CN117177745A - 包含特定hdac6抑制剂和至少一种ctla4检查点抑制剂的组合 - Google Patents

包含特定hdac6抑制剂和至少一种ctla4检查点抑制剂的组合 Download PDF

Info

Publication number
CN117177745A
CN117177745A CN202280027381.5A CN202280027381A CN117177745A CN 117177745 A CN117177745 A CN 117177745A CN 202280027381 A CN202280027381 A CN 202280027381A CN 117177745 A CN117177745 A CN 117177745A
Authority
CN
China
Prior art keywords
combination
ctla
tumor
itf3756
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280027381.5A
Other languages
English (en)
Chinese (zh)
Inventor
G·福萨蒂
F·莱昂尼
P·S·波齐
E·加尔比亚蒂
C·施泰因屈勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Italfarmaco SpA
Original Assignee
Italfarmaco SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Italfarmaco SpA filed Critical Italfarmaco SpA
Publication of CN117177745A publication Critical patent/CN117177745A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202280027381.5A 2021-04-20 2022-04-19 包含特定hdac6抑制剂和至少一种ctla4检查点抑制剂的组合 Pending CN117177745A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT102021000009926 2021-04-20
IT102021000009926A IT202100009926A1 (it) 2021-04-20 2021-04-20 Una combinazione comprendente un inibitore di hdac6 specifico e almeno un inibitore del checkpoint ctla4
PCT/EP2022/060287 WO2022223543A1 (en) 2021-04-20 2022-04-19 A combination comprising a specific hdac6 inhibitor and at least one ctla4 checkpoint inhibitor

Publications (1)

Publication Number Publication Date
CN117177745A true CN117177745A (zh) 2023-12-05

Family

ID=76808052

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280027381.5A Pending CN117177745A (zh) 2021-04-20 2022-04-19 包含特定hdac6抑制剂和至少一种ctla4检查点抑制剂的组合

Country Status (17)

Country Link
US (1) US20240207228A1 (enExample)
EP (1) EP4326259A1 (enExample)
JP (1) JP7902198B2 (enExample)
KR (1) KR20230172001A (enExample)
CN (1) CN117177745A (enExample)
AR (1) AR125356A1 (enExample)
AU (1) AU2022262199A1 (enExample)
BR (1) BR112023021125A2 (enExample)
CA (1) CA3213275A1 (enExample)
CL (1) CL2023002894A1 (enExample)
CO (1) CO2023013780A2 (enExample)
IL (1) IL307649A (enExample)
IT (1) IT202100009926A1 (enExample)
MX (1) MX2023012030A (enExample)
PE (1) PE20242078A1 (enExample)
TW (1) TW202308609A (enExample)
WO (1) WO2022223543A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118121704A (zh) * 2024-02-29 2024-06-04 中山大学附属第一医院 假体周围感染治疗靶点及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110546140A (zh) * 2017-04-14 2019-12-06 意大发马克股份公司 选择性hdac6抑制剂

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190022203A1 (en) 2016-01-11 2019-01-24 Turnstone Limited Partnership Oncolytic virus and checkpoint inhibitor combination therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110546140A (zh) * 2017-04-14 2019-12-06 意大发马克股份公司 选择性hdac6抑制剂

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118121704A (zh) * 2024-02-29 2024-06-04 中山大学附属第一医院 假体周围感染治疗靶点及其应用
CN118121704B (zh) * 2024-02-29 2024-12-17 中山大学附属第一医院 假体周围感染治疗靶点及其应用

Also Published As

Publication number Publication date
CL2023002894A1 (es) 2024-03-15
TW202308609A (zh) 2023-03-01
CO2023013780A2 (es) 2023-11-10
WO2022223543A1 (en) 2022-10-27
IL307649A (en) 2023-12-01
US20240207228A1 (en) 2024-06-27
IT202100009926A1 (it) 2022-10-20
MX2023012030A (es) 2023-10-24
BR112023021125A2 (pt) 2023-12-12
JP2024515100A (ja) 2024-04-04
PE20242078A1 (es) 2024-10-18
EP4326259A1 (en) 2024-02-28
AR125356A1 (es) 2023-07-12
CA3213275A1 (en) 2022-10-27
KR20230172001A (ko) 2023-12-21
AU2022262199A1 (en) 2023-09-21
JP7902198B2 (ja) 2026-08-07

Similar Documents

Publication Publication Date Title
EP2882440B1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
JP2022531939A (ja) がんを処置する方法
JP6911047B2 (ja) がんの処置のための、Ｎｏｔｃｈ阻害剤およびＣＤＫ４／６阻害剤の併用療法
TWI873485B (zh) 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案
KR20180126497A (ko) 치환된 아미노퓨린 화합물, 이의 조성물, 및 그것에 의한 치료 방법
US11224608B2 (en) Compounds and methods for treating cancer
EP3582811B1 (en) Dosing schedule of a wnt inhibitor and an anti-pd-1 antibody molecule in combination
JP2021502415A (ja) 癌の処置のためのアパチニブを用いる併用療法
EP4257609A1 (en) Combination therapies based on pd-1 inhibitors and sik3 inhibitors
JP2019527236A (ja) 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与
CA3141869A1 (en) Methods of treating cholangiocarcinoma
US20240207228A1 (en) A combination comprising a specific hdac6 inhibitor and at least one ctla4 checkpoint inhibitor
US10682339B2 (en) Pharmaceutical compositions directly targeting FKBP52 for the treatment of prostate cancer and methods of using same
WO2023281413A1 (en) Methods and dosing regimens comprising pf-06873600 for the treatment of cancer
EA050310B1 (ru) Комбинация, содержащая специфический ингибитор hdac6 и по меньшей мере одно антитело к ctla4
AU2024294930A1 (en) Pharmaceutical composition and use thereof
HK40018197A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
HK40011167A (en) Dosing schedule of a wnt inhibitor and an anti-pd-1 antibody molecule in combination
HK40011167B (en) Dosing schedule of a wnt inhibitor and an anti-pd-1 antibody molecule in combination
BR112015002384B1 (pt) Combinações farmacêuticas compreendendo um inibidor de b-raf e um inibidor de egfr, e seus usos
HK1204976B (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination